FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA® Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Esophageal and Gastroesophageal Junction Cancer Pharmaceutical Investing
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan Biotech Investing
Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD Biotech Investing
Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform Medical Device Investing
Bristol Myers Squibb Strengthens its Commitment to the Environment with New Corporate Goals Biotech Investing
KEYTRUDA® Plus LENVIMA® Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced... Pharmaceutical Investing
Kite's Tecartus Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe Biotech Investing
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Biotech Investing
Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® Biotech Investing
Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test Medical Device Investing
Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study Biotech Investing
